INTRODUCTION {#sec1-1}
============

Total anomalous pulmonary venous connection (TAPVC) is one of the common cyanotic congenital heart defects that manifests during infancy.\[[@ref1]\] The surgical correction includes rerouting of pulmonary veins to the left atrium, ligation of the vertical vein (VV), and closure of interatrial communication. Chronically under filled left atrium and left ventricle may cause hemodynamic instability while coming off cardiopulmonary bypass.\[[@ref2]\] In some cases of supracardiac TAPVC, keeping the VV patent may prevent acute pulmonary edema and pulmonary venous hypertension in the immediate postoperative period.\[[@ref3]\] We report three cases of transcatheter closure of persistent VV after TAPVC repair.

MATERIALS AND METHODS {#sec1-2}
=====================

Cases {#sec2-1}
-----

The baseline characteristics of the cases are given in [Table 1](#T1){ref-type="table"}. All three patients underwent complete clinical examination including transthoracic echocardiography \[[Figure 1](#F1){ref-type="fig"}\].

###### 

Baseline characteristics of the cases

![](APC-8-221-g001)

![Transthoracic echocardiogram in Case 2 showing (A) Dilated right heart in apical four chambered view, (B) Patent vertical vein in high parasternal view](APC-8-221-g002){#F1}

Procedure {#sec2-2}
---------

A detailed diagnostic cardiac catheterization study was done in all three cases including quantification of the shunt by Fick\'s method, estimation of pulmonary vascular resistance, recording of pull-back pressures from left atrial (LA) to VV, and trial occlusion. The patent VV was occluded using a 24 mm Amplatzer sizing balloon in both cases of repaired supracardiac TAPVC and with Tyshak II balloon (10 mm × 20 mm) in the case with mixed TAPVC. A separate femoral venous access was taken to measure the pulmonary artery (PA) wedge pressure using Swan-Ganz catheter. The cardiac output, systemic and PA wedge pressures were measured 10 min after trial occlusion. The hemodynamics remained stable during trial occlusion. Selective VV injections and levophase of PA showed dilated patent VV and good communication between LA and VV. All three cases were found to be suitable for transcatheter closure of patent VV after the diagnostic study.

Elective transcatheter closure of the patent VV was planned after obtaining informed consent. A left jugular vein, femoral vein, and femoral artery access were obtained in all cases. Levophase of PA angiogram and selective VV injections were done for reference.

### Case 1 {#sec3-1}

A 9 Fr short sheath was introduced into the patent VV using guide wire \[[Figure 2a](#F2){ref-type="fig"}\]. A 22 mm Cera vascular plug (LifeTech sciences, Shenzhen, China) was selected. This ensured a device diameter 1.6-1.8 times larger than the stretched balloon diameter of the VV. The position was confirmed by angiogram \[Figure [2b](#F2){ref-type="fig"}--[d](#F2){ref-type="fig"}\].

![Fluoroscopy and cine angiogram steps of transcatheter closure of patent vertical vein in Case 1: (A) Access from left internal jugular vein showing guide wire position and Berman catheter in the left pulmonary artery. (B) The vascular plug is being deployed partially through the sheath from left jugular vein. (C) Pulmonary artery levophase is showing the well-positioned device and unobstructed pulmonary venous flow to left atrium. (D) Hand injection through the sheath showing the proximal end of the device at the level of innominate vein](APC-8-221-g003){#F2}

### Case 2 {#sec3-2}

Right femoral venous access was used for the procedure. Initially, the VV was entered using a multipurpose catheter. However, the catheter tip broke and embolized into the right PA during the exchange. Subsequently, an 8 Fr Mullins sheath (Cook Medical Corp.) was positioned in the VV and a 20 mm Amplatzer vascular plug II (St. Jude Medical Inc., MN, USA) was deployed. However, the procedure was abandoned due to obstruction of the left upper pulmonary vein by the distal disc of the device \[Figure [3a](#F3){ref-type="fig"} and [b](#F3){ref-type="fig"}\]. The embolized tip of the multipurpose catheter was removed using a 3 mm coronary snare. The procedure was re-attempted 2 days later from the left jugular venous access using a 9 Fr short sheath. A 22 mm Cera vascular plug (Lifetech scientific, Shenzhen, China) was deployed in the VV and its position confirmed in levophase of left PA angiogram \[[Figure 4](#F4){ref-type="fig"}\]. The pulmonary venous flow was unobstructed and drained to the LA.

![(A) Cine angiogram of Case 2 showing injection in the vertical vein using pigtail catheter, (B) closure of patent vertical vein using Amplatzer vascular plug II causing impingement of pulmonary vein by the distal disc](APC-8-221-g004){#F3}

![(A) Levophase of pulmonary artery injection showing the well-positioned device in the vertical vein and unobstructed pulmonary venous flow. (B) Follow-up evaluation by computed tomography scan showing the device position and left pulmonary veins to left atrium](APC-8-221-g005){#F4}

### Case 3 {#sec3-3}

An 8 Fr short sheath was placed in the left jugular vein to close the re-canalized VV in a child with surgically corrected mixed TAPVC. A 16 mm Cera vascular plug was used for closure and confirmed on levogram of left PA injection \[[Figure 5](#F5){ref-type="fig"}\].

![(A) Cine angiogram is showing balloon occlusion of the vertical vein. Unobstructed flow into the left atrium from the left upper pulmonary vein (black arrow) is seen. (B) Complete occlusion after device closure is seen during pulmonary artery levophase](APC-8-221-g006){#F5}

All patients were discharged 24 h after the procedure and advised to continue oral aspirin for 6 months.

RESULTS {#sec1-3}
=======

The procedure was successful in all cases. The baseline Qp/Qs and mean PA pressures were \<2:1 and \<20 mm Hg, respectively, in all cases. Immediate shunt occlusion was achieved in all three cases. There was no major procedure related complications. Minor procedural difficulties were encountered during closure in Case 2. The Amplatzer vascular plug II could not be positioned as the distal disc was projecting into left pulmonary vein despite multiple attempts. It was thought to be due to the trilobed nature of the device and subsequently changed to Cera vascular plug. The multipurpose catheter tip broke during the exchange to a stiff guide wire and was successfully retrieved using a 3 mm coronary snare.

Follow-up evaluation by transthoracic echocardiography showed no residual shunt, normal cardiac chambers, and normal pulmonary venous flow to the left atrium in all patients. Computed tomography angiogram during follow-up of Case 2 showed well-positioned device with no pulmonary venous obstruction \[[Figure 4](#F4){ref-type="fig"}\].

DISCUSSION {#sec1-4}
==========

Low cardiac output after TAPVC repair is due to the small and noncompliant left heart, severe right ventricular dysfunction or pulmonary vein obstruction.\[[@ref4]\] Leaving the VV patent in supracardiac TAPVC helps in redistribution of pulmonary venous return until LA compliance improves and maintains cardiac output in the perioperative period. Caspi *et al*. observed favorable outcomes in their small series of 34 patients with infradiaphragmatic TAPVC, leaving the VV patent.\[[@ref5]\] The VV remains patent more often in cases of supracardiac TAPVC, as it provides lesser resistance when compared to the VV of infradiaphragmatic TAPVC. The high resistance of the hepatic capillary bed leads to the eventual cessation of flow through a descending VV.\[[@ref2]\]

A patent VV presents as a pretricuspid shunt and produces right heart dilatation. Even in the absence of anastomotic obstruction from common venous chamber to left atrium, blood tends to flow preferentially from the common venous chamber toward the right atrium instead of the left atrium due to relative differences in the compliances of the right and left ventricles. Patent VV requires closure in the presence of right heart dilation, PA hypertension, or congestive cardiac failure. Narula *et al*. reported successful closure of a large VV using Amplatzer duct occluder and Amplatzer vascular plug II.\[[@ref6][@ref7]\] It is necessary to document stable hemodynamics by test balloon occlusion of a patent VV prior to its closure.

In all our cases, we preferred "Cera" vascular plug fabricated with expanded polytetrafluoroethylene as it molds itself to conform to the shape of the vein. It is difficult to position the tri-lobed Amplatzer vascular plug II within a VV where minimal encroachment by the disc would result in pulmonary venous obstruction. Choice of the device depends upon the size and shape of the vein. In all cases, the left jugular venous approach was preferred as it was in anatomical alignment with the VV. This minimized catheter manipulation and allowed easier device deployment.

Comment {#sec2-3}
-------

Late presentation of patent VV mimics pretricuspid shunt due to passive shunt from the pulmonary vein to systemic vein. Exercise intolerance, fatigability, and the presence of right heart volume overload may warrant closure. The endovascular closure is preferred due to the location and anatomical nature of this venous structure. Transcatheter closure through left internal jugular approach appears to be simple due to the alignment of the delivery sheath during vascular plug deployment.
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